Merck KGaA's Exploring Of DNA-PK In Cancer ‘Unchanged’ By Vertex Gene-Editing Deal
Executive Summary
Merck KGaA says a gene-editing deal last month with Vertex Pharma involving DNA-dependent protein kinase inhibitors will not alter its plans to investigate DNA-PK compounds in cancer, to try to enhance the efficacy of many commonly used DNA-damaging agents.